Cohort Profile Update: Lifelines, a three-generation cohort study and biobank
Abstract
Cohort Profile Update: Lifelines, a threegeneration cohort study and biobank Anna Sijtsma,* Johanna Rienks , Pim van der Harst, Gerjan Navis, Judith GM Rosmalen and Aafje Dotinga Lifelines Cohort Study, Roden, The Netherlands, Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands, Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands, Department of Nephrology, University Medical Center Groningen, Groningen, The Netherlands and Departments of Psychiatry and Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
- Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.